Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study

OBJECTIVES: Trastuzumab, a humanized monoclonal antibody that binds human epidermal growth factor receptor 2 (HER2), dramatically improves the clinical outcomes of HER2-positive breast cancer. Emerging evidence implied that the clinical behavior and sensitivity to targeted agents in HER2-positive br...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yunchao, Sun, Tao, Wan, Donggui, Sheng, Lijun, Li, Wei, Zhu, Huayun, Li, Yanping, Lu, Janice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648606/
https://www.ncbi.nlm.nih.gov/pubmed/26648738
http://dx.doi.org/10.2147/OTT.S91166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648606/
https://www.ncbi.nlm.nih.gov/pubmed/26648738
http://dx.doi.org/10.2147/OTT.S91166

Ejemplares similares